AstraZeneca’s Fasenra Approved in EU for Treating Rare Vasculitis, Offering New Hope for EGPA Patients

(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and severe form of vasculitis. The approval follows positive results from the MANDARA Phase … Read the full press release →